je.st
news
Tag: merck
Merck KGaA's (MKGAY) "Neutral" Rating Reaffirmed at Goldman Sachs
2016-02-06 15:04:08| Biotech - Topix.net
's stock had its "neutral" rating reissued by research analysts at Goldman Sachs in a note issued to investors on Saturday, AnalystRatings.Net reports. They currently have a $56.00 target price on the stock, down from their previous target price of $60.00.
Tags: rating
neutral
goldman
sachs
Merck beats 4Q profit forecast, misses Street view on sales
2016-02-03 14:37:56| Biotech - Topix.net
In this Thursday, Feb. 28, 2013, file photo, a Merck logo is seen on a scientist's lab coat in West Point, Pa. Merck reports financial results on Wednesday, Feb. 3, 2016.
Tags: view
sales
street
profit
Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
2016-02-03 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Fourth-Quarter 2015 GAAP EPS was $0.35; Fourth-Quarter Non-GAAP EPS was $0.93, an Increase of 7 Percent; Full-Year 2015 GAAP EPS was $1.56; Full-Year 2015 Non-GAAP EPS was $3.59, an Increase of 3 Percent Fourth-Quarter 2015 Worldwide Sales Were $10.2 Billion, a Decrease of 3 Percent, Including a 7 Percent Negative Impact from Foreign Exchange and 3 Percent Net Favorable Impact from Acquisitions and Divestitures Full-Year 2015 Worldwide Sales Were $39.5 Billion, a Decrease of 6 Percent, Reflecting a 6 Percent Negative Impact from Foreign Exchange and a 3 Percent Net Unfavorable Impact from Acquisitions and Divestitures 2016 Financial Outlook Expects Full-Year 2016 GAAP EPS to be Between $1.96 and $2.23; Expects Non-GAAP EPS to be Between $3.60 and $3.75, Including an Approximately 4 Percent Negative Impact from Foreign Exchange Anticipates Full-Year 2016 Worldwide Sales to be Between $38.7 Billion and $40.2 Billion, Including an Approximately 3 Percent Negative Impact from Foreign Exchange Advanced KEYTRUDA Program sBLA Approval for Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 Expanded Indication for First-Line Treatment of Patients with Unresectable or Metastatic Melanoma Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2015. The past year was one of considerable progress and execution for Merck, said Kenneth C. Frazier, chairman and chief executive officer, Merck. Im excited by the near-term opportunities, as we continue launching important new products like ZEPATIER and KEYTRUDA while augmenting and advancing our pipeline. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Atlas Brown Inc. Has $457,000 Position in Merck & Co., Inc.
2016-01-31 13:19:40| Biotech - Topix.net
Atlas Brown Inc. reduced its position in shares of Merck & Co., Inc. by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,074 shares of the company's stock after selling 528 shares during the period.
Tags: inc
position
brown
atlas
FDA OKs Merck hepatitis C drug, adding to patient choices
2016-01-29 02:48:54| Biotech - Topix.net
Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. The FDA said Merck can begin marketing Zepatier for patients with two of the subtypes the liver-destroying virus, types 1 and 4. The combination pill includes the medications elbasvir and grazoprevir, which attack the virus in two different ways.
Tags: drug
adding
patient
choices
Sites : [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] next »